In the application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, director (government and regulatory affairs) at SII, said the vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
